119th Congress
H.R. 1750
HEARD Act of 2025
- Introduced
- In committee
- Passed House
- Passed Senate
- To President
- Became law
- Sponsor
- Marilyn Strickland(D-WA)
- Introduced
- Feb 27, 2025
- Policy area
- Health
- Committees
- House Committee on Energy and Commerce; House Committee on Natural Resources; House Committee on Ways and Means
- Official text
- Introduced in House · Congress.gov page
Cosponsors (5)
Added later (5)
- Eleanor Holmes Norton (D-DC) · Mar 26, 2025
- Henry C. "Hank" Johnson, Jr. (D-GA) · Mar 26, 2025
- Shri Thanedar (D-MI) · Mar 26, 2025
- Yvette D. Clarke (D-NY) · Aug 29, 2025
- Terri A. Sewell (D-AL) · Sep 2, 2025
Summary
Summary by the Congressional Research Service· describes the “Introduced in House” version
Health Equity and Rare Disease Act of 2025 or the HEARD Act of 2025
This bill establishes Department of Health and Human Services (HHS) grants and other initiatives to address rare diseases or conditions (e.g., those affecting less than 200,000 people in the United States) in racial and ethnic minority populations.
For example, to advance such purposes, the bill establishes within HHS
• grants to public and private nonprofit entities for data collection and public outreach,
• grants to health professions schools to improve health care and minority representation in research regarding rare diseases and conditions,
• grants to tribal epidemiology centers and tribal and urban Indian health centers for research regarding rare diseases and conditions in tribal communities,
• scholarships and educational loan repayment for medical school students who agree to work as health care professionals serving populations with rare diseases or conditions,
• initiatives to coordinate research and other activities across the National Institutes of Health, and
• public health awareness and education campaigns.
Also, the bill requires HHS to submit various reports to Congress on topics including (1) the federal government’s research and public health activities regarding rare diseases or conditions in minority populations, (2) regulatory barriers to treating rare diseases in Medicare beneficiaries of color, and (3) strategies for research and development of treatments for rare diseases or conditions that disproportionately impact minority populations.
Roll-call votes
No recorded votes on this bill.
Actions
- Feb 27, 2025 · House
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Natural Resources, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. - Feb 27, 2025
Introduced in House